Profund Advisors LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Profund Advisors LLC cut its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 5.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 153,237 shares of the biopharmaceutical company’s stock after selling 9,586 shares during the period. Profund Advisors LLC’s holdings in Pfizer were worth $6,706,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Steward Financial Group LLC lifted its position in Pfizer by 315.3% during the second quarter. Steward Financial Group LLC now owns 544 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 413 shares in the last quarter. Worth Asset Management LLC acquired a new position in shares of Pfizer during the 1st quarter valued at $29,000. Goodman Advisory Group LLC acquired a new stake in Pfizer in the 2nd quarter valued at $32,000. Karp Capital Management Corp acquired a new position in shares of Pfizer during the third quarter worth about $27,000. Finally, Johnson Midwest Financial LLC boosted its position in shares of Pfizer by 246.1% in the second quarter. Johnson Midwest Financial LLC now owns 886 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 630 shares during the period. Institutional investors and hedge funds own 67.62% of the company’s stock.

Pfizer Stock Performance

Pfizer stock traded down $0.06 during mid-day trading on Wednesday, hitting $44.65. 4,226,376 shares of the company’s stock traded hands, compared to its average volume of 23,110,918. Pfizer Inc. has a one year low of $41.44 and a one year high of $56.32. The company has a market cap of $250.63 billion, a PE ratio of 8.60, a price-to-earnings-growth ratio of 1.11 and a beta of 0.67. The firm has a 50 day moving average price of $49.68 and a 200 day moving average price of $48.06. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 0.35.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.31. The business had revenue of $22.64 billion during the quarter, compared to analyst estimates of $21.04 billion. Pfizer had a return on equity of 43.95% and a net margin of 29.81%. On average, equities analysts forecast that Pfizer Inc. will post 6.47 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, January 26th. This is a positive change from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a yield of 3.67%. Pfizer’s dividend payout ratio is currently 30.77%.

Analysts Set New Price Targets

Several equities analysts recently commented on PFE shares. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price target on the stock. in a research report on Wednesday, January 4th. Barclays upped their target price on shares of Pfizer from $44.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 2nd. initiated coverage on shares of Pfizer in a report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. JPMorgan Chase & Co. set a $50.00 target price on Pfizer in a research report on Wednesday, January 18th. Finally, Credit Suisse Group set a $54.00 price target on shares of Pfizer in a research note on Wednesday, January 18th. Seven equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from, the company presently has an average rating of “Hold” and a consensus target price of $53.00.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.